TP53 and AIDS dementia complex: In conclusion, our study shows that for patients with stage I ADC, TP53 mutations confer an OS disadvantage compared with wild‐type TP53. For patients with stage I surgically resected ADC, a TP53 mutation might be a potential molecular biomarker of prognosis that can be used with other histologic markers to guide decision‐making about adjuvant therapy.